ABBV vs ADP Stock Comparison

Scores Breakdown

Metric	ABBV	ADP
📈 Growth	26/30	26/30
💰 Profitability	18/20	18/20
🏦 Financial Health	6/20	12/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	8/10	6/10
Overall Score	64/100	74/100

Side-by-Side Summaries

ABBV Analysis	ADP Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, revenues rose from about $4.77B (2024 Q4) to about $5.36B (2026 Q4). Net income progressed from roughly $0.83B to $1.06B, a 28% increase, signaling earnings leverage as the top line expanded. The quarterly path fluctuated—peaking near $5.55B in 2025 Q3/Q4 before settling in the $5.2–$5.36B range—yet the trend remains clearly positive. The Gross Margin held in the high-40s to mid-50s, while Operating Margin stayed in the low- to mid-20s, underpinning a solid profitability trajectory. 💰 Margins & Cash Flow Gross Margin: roughly 46–56% across periods, with a peak around 56%. Operating Margin: generally 20–24%, supporting meaningful operating leverage. Net cash flow from operating activities was consistently positive in most quarters, while investing cash flow was mostly modestly negative and financing activity contributed steady liquidity. 🛡️ Balance Sheet & Liquidity Current assets ($52B) vs current liabilities ($50B) yields a tight but adequate liquidity cushion. Liabilities ($57B) exceed equity ($6B), indicating leverage, but assets and ongoing operating cash flows provide resilience. The balance sheet remains stable with a solid asset base. ⚠️ Key Drivers & Risks Drivers: Recurring payroll/data-processing demand; large installed base and stable cash flows. Risks: Valuation sensitivity to growth momentum; exposure to regulatory shifts or macro cycles.

ABBV Analysis

ADP Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, revenues rose from about $4.77B (2024 Q4) to about $5.36B (2026 Q4). Net income progressed from roughly $0.83B to $1.06B, a 28% increase, signaling earnings leverage as the top line expanded. The quarterly path fluctuated—peaking near $5.55B in 2025 Q3/Q4 before settling in the $5.2–$5.36B range—yet the trend remains clearly positive. The Gross Margin held in the high-40s to mid-50s, while Operating Margin stayed in the low- to mid-20s, underpinning a solid profitability trajectory.

💰 Margins & Cash Flow

Gross Margin: roughly 46–56% across periods, with a peak around 56%.
Operating Margin: generally 20–24%, supporting meaningful operating leverage.
Net cash flow from operating activities was consistently positive in most quarters, while investing cash flow was mostly modestly negative and financing activity contributed steady liquidity.

🛡️ Balance Sheet & Liquidity

Current assets ($52B) vs current liabilities ($50B) yields a tight but adequate liquidity cushion.
Liabilities ($57B) exceed equity ($6B), indicating leverage, but assets and ongoing operating cash flows provide resilience. The balance sheet remains stable with a solid asset base.

⚠️ Key Drivers & Risks

Drivers: Recurring payroll/data-processing demand; large installed base and stable cash flows.
Risks: Valuation sensitivity to growth momentum; exposure to regulatory shifts or macro cycles.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"